Breast cancer survivor offers wisdom at Faulkner satellite center
Call 877-422-3324 today to make an appointment
Make your appointment or second opinion with Dana-Farber today to meet with an onsite specialist.
Can’t get to Boston? Explore our Online Second Opinion service to get expert advice from Dana-Farber oncologists.
Toll-Free Number866-408-DFCI (3324)
Discover the ways to give and how to get involved to support Dana-Farber.
Poet Richard Fox gains insight – and material – through cancer treatment
A family faces cancer in an unfamiliar city – with help
Choosing mastectomy or not: Studying young women's surgical choices
Jeff's targeted therapy has kept his advanced lung cancer at bay.
A group of specialists at the National Cancer Institute recently issued a report calling for a redefinition of the word "cancer," suggesting that it no longer be applied to certain premalignant and non-lethal conditions. Such a change, the panel wrote, may ease the fears of patients, making them less inclined to seek unnecessary and potentially harmful treatments. The findings reinforce earlier studies by Dana-Farber physicians and others.
An example of this kind of condition is ductal carcinoma in situ (DCIS), in which cancerous cells are confined to the milk ducts of the breast. It is the most common form of non-invasive breast cancer, found in more than 60,000 women in the U.S. each year, according to the American Cancer Society.
In this video, Eric Winer, MD, director of the Breast Oncology Center at the Susan F. Smith Center for Women's Cancers at Dana-Farber, answers some common questions about DCIS and its treatment.